Skip to content
OpenCapital
Get started

Madrigal Pharmaceuticals, Inc. MDGL Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

RBC Bearings logo
RBC BearingsRBC
$438.51+47.2%
MSCI logo
MSCIMSCI
$532.62+19.8%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$231.76—
Wintrust Financial logo
Wintrust FinancialWTFC
$44.81+2.4%
MSCI logo
MSCIMSCI
$530.25+20.7%
The Travelers Companies logo
The Travelers CompaniesTRV
$174.08+11.1%

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M—
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M—
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%—
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Madrigal Pharmaceuticals, Inc. (MDGL) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $189.98 in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price increased by 72.6% year-over-year, from $110.04 to $189.98.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 2 years (2023 to 2025), Madrigal Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 39.4% compound annual growth rate (CAGR), from $79.94 to $155.25.